Symptom improvement following gefitinib ('Iressa', ZD1839) therapy in a pretreated patient with non-small-cell lung cancer

被引：0
|
作者：
Pavlakis, N
机构：
[1] Univ Hosp Heraklion, Iraklion, Greece
[2] Univ Crete, Sch Med, Iraklion, Greece
来源：
BRITISH JOURNAL OF CANCER | 2003年 / 89卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S31 / S31
页数：1
相关论文
共 50 条
  • [41] Cell growth after withdrawal of gefitinib ('Iressa', ZD1839) in human lung cancer cells
    Satoh, H
    Ishikawa, H
    Nakayama, M
    Fujiwara, M
    Ohtsuka, M
    Sekizawa, K
    [J]. ONCOLOGY REPORTS, 2004, 12 (03) : 615 - 619
  • [42] Clinically meaningful response to the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer
    Gelibter, A
    Ceribelli, A
    Milella, M
    Mottolese, M
    Vocaturo, A
    Cognetti, F
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 : S28 - S28
  • [43] New hope for patients with non-small-cell lung cancer: gefitinib ('Iressa', ZD 1839) and other innovative therapies
    Goss, G
    [J]. EJC SUPPLEMENTS, 2003, 1 (08): : 1 - 1
  • [44] Refractory non-small-cell lung cancer: clinical experience with gefitinib ('Iressa', ZD1839) in 28 patients who entered the 'Iressa' Expanded Access Programme at the Sydney Cancer Centre
    Boyer, M
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 : S26 - S26
  • [45] Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, 'Iressa') on an expanded access study
    Dongiovanni, Vincenzo
    Dongiovanni, Diego
    Buffoni, Lucio
    Barone, Carla
    Fissore, Camilla
    Addeo, Alfredo
    Larovere, Erika
    Grillo, Raffaella
    Nuzzolo, Gloria
    Schena, Marina
    Bertetto, Oscar
    [J]. ANNALS OF ONCOLOGY, 2005, 16 : 21 - 22
  • [46] Treatment of non-small cell lung cancer with gefitinib ('Iressa', ZD1839): the Greek experience with a compassionate-use program
    Razis, E
    Skarlos, D
    Briasoulis, E
    Dimopoulos, M
    Fountzilas, G
    Lambropoulos, S
    Rigatos, S
    Kopterides, P
    Efstathiou, H
    Tzamakou, E
    Bakoyannis, C
    Pectasides, D
    Makatsoris, T
    Varthalitis, G
    Papadopoulos, S
    Kosmidis, R
    [J]. ANTI-CANCER DRUGS, 2005, 16 (02) : 191 - 198
  • [47] Clinically meaningful response case to the EGFR tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in non small cell lung cancer
    Gelibter, A
    Ceribelli, A
    Milella, M
    Mottolese, M
    Vocaturo, A
    Cognetti, F
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2003, 22 (03) : 481 - 485
  • [48] Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib ('Iressa', ZD1839)
    Tanno, S
    Ohsaki, Y
    Nakanishi, K
    Toyoshima, E
    Kikuchi, K
    [J]. ONCOLOGY REPORTS, 2004, 12 (05) : 1053 - 1057
  • [49] ZD1839 for the treatment of heavily pretreated non-small cell lung cancer.
    Wu, YL
    Yang, X
    Yang, JJ
    Huang, YJ
    Chen, G
    Gu, LJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 701S - 701S
  • [50] Gefitinib (Iressa™, ZD1839) and tyrosine kinase inhibitors -: The wave of the future in cancer therapy
    Penne, K
    Bohlin, C
    Schneider, S
    Allen, D
    [J]. CANCER NURSING, 2005, 28 (06) : 481 - 486
12345